The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.

Following in the footsteps of several pharma companies, life sciences giant Thermo Fisher is doubling down on investments at ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US.

Roche is set to invest $50bn in pharmaceuticals and diagnostics in the US over the coming five years to bolster its presence ...

Biogen Netherlands has received marketing authorisation from the UK MHRA for its Skyclarys to treat Friedreich's ataxia.

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

CDMOs are crucial partners in alum-based vaccine production, managing aseptic filling with precision and efficiency.